KCM
AUPH icon

Kingdon Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Kingdon Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200,000
Closed -$2.77M – 63
2020
Q4 		$2.77M Hold
200,000
– – 0.3% 49
2020
Q3 		$2.95M Hold
200,000
– – 0.33% 53
2020
Q2 		$3.25M Buy
+200,000
New +$3.2M 0.3% 46
2020
Q1 		– Sell
-100,000
Closed -$2.03M – 53
2019
Q4 		$2.03M Buy
+100,000
New +$921K 0.31% 42

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Kingdon Capital Management's AUPH Position: Q3 2021 in Review

Kingdon Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 1,583,208 shares — an estimated $20.5M sold.

Kingdon Capital Management first reported a position in AUPH in Q4 2019 and held it in 7 quarters. The position peaked at $23.7M in Q3 2020. 166 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

  • Kingdon Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Kingdon Capital Management sold 1,583,208 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $20.5M.
  • Kingdon Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Kingdon Capital Management's Aurinia Pharmaceuticals position peaked at $23.7M in Q3 2020.
  • 166 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Kingdon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.